BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22796490)

  • 1. Single-arm phase IIA clinical trials with go/no-go decisions.
    Zhong B
    Contemp Clin Trials; 2012 Nov; 33(6):1272-9. PubMed ID: 22796490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions.
    Chen C; Beckman RA
    J Biopharm Stat; 2009; 19(3):424-36. PubMed ID: 19384686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials.
    Jin H; Wei Z
    Contemp Clin Trials; 2012 Nov; 33(6):1255-60. PubMed ID: 22772088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A varying-stage adaptive phase II/III clinical trial design.
    Dong G
    Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexible designs for phase II comparative clinical trials involving two response variables.
    Bersimis S; Sachlas A; Papaioannou T
    Stat Med; 2015 Jan; 34(2):197-214. PubMed ID: 25274584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
    Masaki N; Koyama T; Yoshimura I; Hamada C
    J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-sample proportion testing procedures for hypothesis of inequality.
    Zhong W; Zhong B
    J Biopharm Stat; 2013 May; 23(3):604-17. PubMed ID: 23611198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials.
    Englert S; Kieser M
    Stat Med; 2015 Jun; 34(13):2128-37. PubMed ID: 25781860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive designs for single-arm phase II trials in oncology.
    Englert S; Kieser M
    Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curtailed two-stage designs with two dependent binary endpoints.
    Chen CM; Chi Y
    Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An adjustment for patient heterogeneity in the design of two-stage phase II trials.
    Sposto R; Gaynon PS
    Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.